Japan ensures transparency in drug quality audits through stringent regulatory frameworks, such as the Pharmaceuticals and Medical Devices Agency (PMDA) guidelines. Regular inspections, public reporting of audit outcomes, and adherence to Good Manufacturing Practices (GMP) standards are enforced. Collaboration with international bodies further enhances transparency and trust in the pharmaceutical sector.